课题基金 / 基金详情

Cardiovascular and Ocular Adverse Events Associated with New Treatments for Age-Related Macular Degeneration

Cardiovascular and Ocular Adverse Events Associated with New Treatments for Age-Related Macular Degeneration
与年龄相关性黄斑变性新疗法相关的心血管和眼部不良事件
批准号：
202140
负责人：
Campbell Robert J
金额：
$12.89万
依托单位：
Queen's University (Kingston, Ontario)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2010
资助国家：
加拿大
项目状态：
已结题
起止时间：
2010-03-01 至 2013-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=202140&lang=en
关键词：
Administarative Database Research Adverse Drug Events Age-Related Macular Degeneration Drug Safety Ophthalmology Vascular Endothelial Growth Factor Inhibitors

项目摘要

项目成果

Campbell Robert J的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Blindness is a dreaded condition that costs Canada $15.8 billion annually. Age related macular degeneration (ARMD) is the leading cause of blindness in our country. In severe cases of ARMD, abnormal blood vessels grow beneath and within the retina, causin
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Comparative effectiveness of newer oral diabetes medications in preventing advanced diabetic retinopathy
Comparative safety of aflibercept and ranibizumab in the treatment of retinal diseases
海外基金